Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a human IgG1 Fc tag at the N-terminus, followed by an Avi tag (Avitag™)
The protein has a calculated MW of 107.7 kDa. The protein migrates as 100-105 kDa and 120-140 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Biotinylated Human PSMA Protein, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
The purity of Biotinylated Human PSMA Protein, Fc,Avitag (Cat. No. PSA-H82F7) is more than 80% and the molecular weight of this protein is around 220-260 kDa verified by SEC-MALS.
Immobilized Monoclonal Anti-Human PSMA Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Human PSMA Protein, Fc,Avitag (Cat. No. PSA-H82F7) with a linear range of 0.5-16 ng/mL (QC tested).
Immobilized Biotinylated Human PSMA Protein, Fc,Avitag (Cat. No. PSA-H82F7) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-Human PSMA Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (Routinely tested).
Price(USD) : $350.00
Price(USD) : $1520.00
Price(USD) : $32.00
Price(USD) : $137.00
Price(USD) : $50.00
Price(USD) : $120.00
Price(USD) : $138.00
Price(USD) : $230.00
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Capromab pendetide | lndium-CYT-356; Indium-111-CYT-356; CYT-356; 111In CYT-356 | Approved | Eusa Pharma | ProstaScint | United States | Prostatic Neoplasms | Cytogen Corp | 1996-10-28 | Prostatic Neoplasms | Details |
Lutetium (177Lu) vipivotide tetraxetan | PSMA-617-[177Lu]; Lutetium-177-PSMA-617; 177-Lu-PSMA-617; AAA-617; Lu-177- RLT | Approved | Radiomedix Inc | PLUVICTO | United States | Prostatic Neoplasms, Castration-Resistant | Advanced Accelerator Applications Usa Inc | 2022-03-23 | Carcinoma, Verrucous; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Carcinoma, Squamous Cell; Neoplasm Metastasis | Details |
Piflufolastat F 18 | Approved | Johns Hopkins University | Pylarify | United States | Prostatic Neoplasms | Progenics Pharmaceuticals Inc | 2021-05-26 | Carcinoma, Renal Cell; Prostatic Neoplasms; Breast Neoplasms; Genital Neoplasms, Female; Neoplasm Metastasis; Adenocarcinoma | Details | |
Ga-68 PSMA-11 | Ga-68-PSMA-11; Ga-68-PSMA; 68Ga-HBED-CC-PSMA11 | Approved | Radiomedix Inc | Gallium Ga 68 Psma-11, Illuccix, ILLUCCIX, Locametz | United States | Prostatic Neoplasms | Telix Pharmaceuticals Ltd, University Of California, San Francisco Foundation | 2020-12-01 | Solid tumours; Neoplasm Recurrence, Local; Carcinoma, Renal Cell; Carcinoma, Ovarian Epithelial; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Breast Neoplasms; Prostatic Neoplasms; Neoplasm Metastasis; Carcinoma, Hepatocellular | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CART-PSMA-TGFbRDN (University of Pennsylvania) | Phase 1 Clinical | University Of Pennsylvania | Prostatic Neoplasms | Details | |
Autologous T-cell therapy (anti-PSMA-CD3), Roger Williams Medical Center | Phase 1 Clinical | Roger Williams Medical Center | Prostatic Neoplasms | Details | |
68Ga-PSMA-R2 (Advanced Accelerator Applications SA) | Clinical | Advanced Accelerator Applications Sa | Prostatic Neoplasms | Details | |
TLX-592 | TLX-592 | Phase 2 Clinical | Telix Pharmaceuticals Ltd | Prostatic Neoplasms | Details |
CONV-01-alpha + PSMA I&T | Phase 2 Clinical | Convergent Therapeutics Inc | Prostatic Neoplasms | Details | |
ARX-517 | ARX-517 | Phase 1 Clinical | Ambrx Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
123-I-MIP-1095 | 123-I-MIP-1095 | Details | |||
123I-MIP-1072 | 123-I-MIP-1072 | Details | |||
[131I]MIP-1095 | 1095; [131I]MIP-1095; [131I]MIP-1466 | Progenics Pharmaceuticals Inc | Details | ||
JNJ-63898081 | JNJ-8081; JNJ-63898081 | Janssen Global Services Llc | Details | ||
177Lu-PSMA-R2 | 177Lu-PSMA-R2; 177Lu-PSMA-SR6; AAA-602 | Phase 2 Clinical | Advanced Accelerator Applications Sa | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
Pelgifatamab corixetan | BAY-2315497 | Phase 1 Clinical | Bayer AG | Prostatic Neoplasms | Details |
LAVA-1207 | LAVA-1207 | Phase 2 Clinical | Vu University Medical Center | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
177Lu-rhPSMA-10.1 | 177Lu-rhPSMA-10.1; (177Lu) rhPSMA-10.1 | Phase 2 Clinical | Blue Earth Therapeutics Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms; Urogenital Neoplasms; Prostatic Diseases | Details |
Anti-PSMA CAR T-cell therapy (TNK Therapeutics) | Phase 1 Clinical | Sorrento Therapeutics Inc | Neoplasms | Details | |
INO-5401 | INO-5401 | Phase 2 Clinical | Inovio Pharmaceuticals Inc | Glioblastoma; Carcinoma, Transitional Cell | Details |
CBP-1018 | CBP-1018 | Phase 1 Clinical | Coherent Biopharma Suzhou Co Ltd | Solid tumours; Carcinoma, Renal Cell; Prostatic Neoplasms; Lung Neoplasms | Details |
68Ga-PSMA-IRDye | TLX591-Sx | Phase 2 Clinical | Telix Pharmaceuticals Ltd | Prostatic Neoplasms | Details |
CCW-702 | CCW-702 | Phase 1 Clinical | The Scripps Research Institute Inc, Abbvie Inc | Prostatic Neoplasms | Details |
177Lu-EB-vipivotide tetraxetan | 177-Lu-EB-PSMA-617 | Phase 1 Clinical | National Institute For Biomedical Imaging And Bioengineering (Nibib), Peking Union Medical College Hospital | Carcinoma, Renal Cell; Prostatic Neoplasms, Castration-Resistant; Carcinoma, Adenoid Cystic; Prostatic Neoplasms | Details |
PSMA-CART cell therapy (Shanghai Bioray Laboratory) | Phase 1 Clinical | Bioray Laboraytories Inc | Prostatic Neoplasms | Details | |
P28z-CAR | P28z-CAR | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center, United States Department Of Defense | Prostatic Neoplasms | Details |
67Cu-SAR-bisPSMA (Clarity Pharmaceuticals) | Phase 2 Clinical | Clarity Pharmaceuticals Ltd | Prostatic Neoplasms, Castration-Resistant | Details | |
64Cu-SAR-bisPSMA (Clarity Pharmaceuticals) | Phase 2 Clinical | Clarity Pharmaceuticals Ltd | Prostatic Neoplasms, Castration-Resistant | Details | |
GD2/PSMA Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR GD2/PSMA | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Solid tumours | Details |
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell | Details | |
PSMA/CD70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR PSMA/CD70 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Neoplasms | Details |
Gallium-68 PSMA-617 | 225 Ac-PSMA-617; 68Ga-PSMA-617; 68Ga-DKFZ-617; 68Ga-DKFZ-PSMA -617; 68Ga-DOTA-PSMA-DKFZ -617; Gallium-68-PSMA-617; PSMA-617-[68Ga] | Phase 3 Clinical | Peking Union Medical College Hospital | Prostatic Neoplasms | Details |
89Zr-DFO-huJ591 | Zr89-J591; 89Zr-DFO-J591; 89Zr-DFO-huJ591 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center | Prostatic Neoplasms | Details |
225 Actinium PSMA 617 (Novartis) | 225 Actinium PSMA-617; 225Ac-PSMA 617; AAA 817; 225Ac-PSMA-617 | Phase 1 Clinical | Novartis Pharma Ag, Endocyte Inc, Advanced Accelerator Applications Sa | Prostatic Neoplasms, Castration-Resistant | Details |
CC-1 | CC-1 | Phase 2 Clinical | The University Of Tubingen, German Cancer Research Center (Dkfz) | Prostatic Neoplasms, Castration-Resistant; Carcinoma, Squamous Cell | Details |
Lu-177-DGUL | PSMA-D GUL; Lu-177-DGUL; 177Lu-DOTA-GUL | Phase 2 Clinical | Cellbion Co Ltd | Neoplasms; Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
4SCAR-PSMA T cell therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Neoplasms | Details | |
JANX-007 | JANX-007; PSMA-TRACTr | Phase 1 Clinical | Janux Therapeutics Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
HPN-424 | HPN-424 | Phase 2 Clinical | Harpoon Therapeutics | Prostatic Neoplasms | Details |
Lutetium-177-PSMA-I&T | Phase 2 Clinical | Radboud University Nijmegen | Prostatic Neoplasms | Details | |
Ga-68-NGUL | Phase 2 Clinical | Cellbion Co Ltd | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details | |
[177Lu]Ludotadipep | Phase 2 Clinical | Futurechem | Prostatic Neoplasms, Castration-Resistant | Details | |
TNB-585 | AMG-340; TNB-585 | Phase 1 Clinical | Teneobio Inc, Amgen Inc | Prostatic Neoplasms, Castration-Resistant | Details |
REGN-4336 | REGN-4336 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
REGN-5678 | REGN-5678 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Prostatic Neoplasms, Castration-Resistant | Details |
18F-PSMA-1007 | 18F-PSMA-1007 | Phase 3 Clinical | Deutsches Krebsforschungszentrum | Prostatic Neoplasms | Details |
Acapatamab | AMG-160 | Phase 2 Clinical | Amgen Inc | Prostatic Neoplasms, Castration-Resistant; Carcinoma, Non-Small-Cell Lung | Details |
JNJ-80038114 | JNJ-80038114 | Phase 1 Clinical | Janssen Research & Development Llc | Prostatic Neoplasms | Details |
Fluorine-18-CTT-1057 | CTT-1057; 18F-CTT1057; CTT-1057-18F; CTT-1057-F-18 | Phase 3 Clinical | Washington University, Cancer Targeted Technology Llc | Recurrence; Carcinoma, Renal Cell; Prostatic Neoplasms | Details |
[177Lu]-CTT-1403 | CTT-1403; [177Lu]CTT1403; 177Lutetium CTT1403; [177Lu]CTT-1403 | Phase 1 Clinical | Cancer Targeted Technology Llc | Prostatic Neoplasms | Details |
ATL-101 | MLN-591RL; ATL-101; huJ-591; MLN-591; J-591; Lu-177-J591; 177Lu-J591; 90Y-J591; muJ-591 | Phase 2 Clinical | Weill Medical College of Cornell University | Ovarian Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Esophageal Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Glioma; Carcinoma, Non-Small-Cell Lung | Details |
177Lu-DOTA-rosopatamb | TLX591; 177Lu-DOTA-TLX591-CHO | Phase 3 Clinical | Telix Pharmaceuticals Ltd | Prostatic Neoplasms | Details |
177Lu-HTK03170 | 177Lu-HTK03170 | Phase 2 Clinical | British Columbia Cancer Agency | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
68Ga-labeled NY108 | 68-Ga-labeled NY-108 | Phase 1 Clinical | Affiliated Hospital Of Jiangnan University | Prostatic Neoplasms | Details |
[Lu177]-PNT-2002 | PNT-2002 | Phase 3 Clinical | Point Biopharma Inc | Prostatic Neoplasms, Castration-Resistant; Prostatic Neoplasms | Details |
225Ac-J591 | 225Ac-DOTA-J591; 225Ac-J591; CONV 01-α | Phase 2 Clinical | Cornell University | Prostatic Neoplasms | Details |
This web search service is supported by Google Inc.